Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 6Neoplasm Metastasis 6Pancreatic Neoplasms 2Lung Neoplasms 1Lung Diseases 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × demcizumab × Clear all
NCT02289898 2020-09-28

YOSEMITE

Mereo BioPharma

Phase 2 Completed
207 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01189929 2020-09-09

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Mereo BioPharma

Phase 1 Completed
57 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡